LLYEli Lilly and CompanyNot started yet
A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer
Urinary Bladder Neoplasms · Urologic Neoplasms · Receptor, Fibroblast Growth Factor, Type 3
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 161 (planned)
- Started
- Dec 2026
- Main results expected
- Jul 2028
- Fully finished
- Mar 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants with LG IR NMIBC with Complete Response
Measured over: Baseline, 2 Years
Number of Participants with LG UTUC with Complete Response
Measured over: Baseline, 2 Years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07827612 · record last updated 2026-10-08 · checked 2026-11-09 15:42 UTC